Ceftazidime静注後の前立腺組織内および血清中濃度について

Abstract

前立腺肥大症患者37例を三群に分け, それぞれCAZ 1 gを術前60分, 120分および240分にone shot静注し, 前立腺組織内および血清中濃度をTUR-Pの際に測定した.1)投与後60分にて採取した群:前立腺組織内濃度23.4±7.4 μg/g, 血清中濃度45.0±15.9 μg/ml, P/S 0.58±0.27であった.2) 120分:それぞれ18.0±8.2 μg/g, 39.8±21.3 μg/ml, 0.53±0.31.3) 240分群:それぞれ11.3±3.2 μg/g, 22.3±9.6 μg/ml, 0.60±0.31であった.組織内濃度を起炎菌のMIC80と比較した場合, E. coliをはじめとする各種グラム陰性菌のMIC80を上回っていた.一方, 各種標準菌に対しても, グラム陰性菌をはじめとしグラム陽性菌まで, 広範囲の細菌のMICを上回っていた.したがってCAZは急性前立腺炎やTUR-Pの術前の感染予防に対し有用な薬剤である

The present study was undertaken to evaluate the penetration of Ceftazidime (CAZ) into prostatic tissue (P) and serum (S). Thirty-seven patients with benign prostatic hypertrophy took part in this study. CAZ was administered intravenously at a dose of 1g preoperatively. Blood samples were taken simultaneously at the time of tissue sampling by transurethral resection of the prostate (TUR-P). The patients were divided into 3 groups. In group 1 (twelve patients), intravenous injection of the drug was given 60 minutes before tissue sampling. The mean concentrations of CAZ were 23.4 +/- 7.4 micrograms/g in the prostatic tissue and 45.0 +/- 15.9 micrograms/ml in the serum. In group 2 (thirteen patients), the injections were given 120 minutes before tissue sampling. The mean concentrations of CAZ were 18.0 +/- 8.2 micrograms/g in the prostatic tissue and 39.8 +/- 21.3 micrograms/ml in the serum. In group 3 (twelve patients), the injections were given 240 minutes before tissue sampling. The mean concentrations of CAZ were 11.3 +/- 3.2 micrograms/g in the prostatic tissue and 22.3 +/- 9.6 micrograms/ml in the serum. These findings indicate that CAZ is useful for the treatment of prostatitis and preventive medication before TUR-P.